二甲双胍的药物基因组学研究进展

Reviewed the Progress of Pharmacogenomics Research on Metformin

近年来,有关2型糖尿病的诊疗指南不断更新,药物治疗策略日趋个体化。《中国2型糖尿病防治指南(2017版)》于2018年1月正式发布。新版指南进一步突出了二甲双胍在降糖治疗路径中的基石地位。然而,大量的临床研究结果表明:作为首选降糖药物,二甲双胍存在着显著的药物反应个体差异性。究其主因,学者多归转于遗传因素。相关研究绝大部分关注在药物靶蛋白、药物代谢酶、药物转运体蛋白的基因组学方面。因此,为丰富人们对二甲双胍药物反应个体差异性的认识,本文拟从药物基因组学的角度来综述二甲双胍的研究进展。

In recent years,the guidelines for the diagnosis and treatment of type 2 diabetes mellitus(T2DM)have been constantly updated,and the drug treatment strategies have become increasingly individualized.Guidelines for the Prevention and Treatment of Type 2 Diabetes in China(2017 Edition)was officially published in January 2018.The new guidelines further highlight the cornerstone role of metformin in the treatment of hypoglycemia.However,massive clinical studies have shown that metformin,as the preferred hypoglycemic drug,has significant individual differences in drug response.Analyzing the main reasons,scholars mostly think that genetic factors are responsible for it,and most of the related studies focus on the genomics of drug target proteins,drug metabolic enzymes and drug transporter proteins.Therefore,in order to enrich people’s understanding of individual differences about metformin drug response,this article reviewed the research progress of metformin from the perspective of pharmacogenomics.